Compass Pathways 

Yahoo Finance • 20 days ago

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect in treatment resistant depression (TRD), with a generally well-tolerated and safe profile Across t... Full story

Yahoo Finance • 2 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Organigram Secured C$65.2 Million Strategic Investment from British American Tobacco After the Company Agreed to Acquire Sanity Group Canopy Growth Secured Shareholder Backing for MTL Cannabis Acquisition Gr... Full story

Yahoo Finance • 2 months ago

Cathie Wood Pours $24 Million to This AI Software Stock

This article first appeared on GuruFocus. Cathie Wood's ARK Invest added to Figma (NYSE:FIG) and trimmed DraftKings (NASDAQ:DKNG) on Feb. 19, as part of a broader portfolio reshuffle. ARK funds bought about $24 million of Figma shares af... Full story

Yahoo Finance • 2 months ago

Why Did Compass Pathways Stock Rocket Higher Today?

It's been a long road for Compass Pathways(NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the company received breakthrough therapy de... Full story

Yahoo Finance • 2 months ago

Biggest stock movers Tuesday: ZIM, CMPS, and more

[Technical Price Chart Data Analysis Showing 2020 Corona Virus Covid-19 Stock Market Crash] Stock futures dipped Tuesday morning amid a holiday-shortened trading week, spotlighting key economic data and corporate earnings ahead. Here are... Full story

Yahoo Finance • 6 months ago

Psychedelic stocks gain after positive remarks from GOP Senator in North Carolina

[Magic Mushroom stock images] Betka82/iStock via Getty Images Companies focused on psychedelic medicines traded higher on Tuesday after Marijuana Moment reported Bob Brinson, a Republican state senator in North Carolina, as saying that hi... Full story

Yahoo Finance • 7 months ago

Design Therapeutics Appoints Justin Gover to Board of Directors

CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of ind... Full story

Yahoo Finance • 8 months ago

Cathie Wood's ARK makes major moves in Trade Desk and Block stock

Cathie Wood’s ARK ETFs have once again made significant trades on Tuesday, 12 August 2025, with a major focus on tech and biotech stocks. The most substantial trade of the day was the purchase of 738,367 shares of Trade Desk Inc (NASDAQ:... Full story

Yahoo Finance • 8 months ago

Compass Pathways price target lowered to $40 from $45 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Compass Pathways (CMPS) to $40 from $45 and keeps a Buy rating on the shares. Compass confirmed that no further development is planned in anorexia nervosa following completion of the Phase... Full story

Yahoo Finance • 8 months ago

Cathie Wood's ARK ETFs shuffle RBLX, COIN, and BMNR stocks

Cathie Wood’s ARK ETFs have made significant moves in the stock market on Friday, August 1, 2025, with a particular focus on tech and biotech companies. Leading the trades was a massive purchase of Coinbase Global Inc (NASDAQ:COIN) share... Full story

Yahoo Finance • 8 months ago

COMPASS Pathways ADS Q2 2025 Earnings Preview

* COMPASS Pathways ADS (NASDAQ:CMPS [https://seekingalpha.com/symbol/CMPS]) is scheduled to announce Q2 earnings results on Thursday, July 31st, before market open. * The consensus EPS Estimate is -$0.37 [https://seekingalpha.com/symbo... Full story

Yahoo Finance • 9 months ago

Cathie Wood's ARK buys Tempus AI stock, sells Block and Roku

Cathie Wood’s ARK ETFs disclosed their daily trades for Wednesday, July 9th, 2025, with a significant focus on the tech and healthcare sectors. In the largest transaction of the day, ARK increased its position in Tempus AI Inc (NYSE:TEM),... Full story

Yahoo Finance • 9 months ago

Cathie Wood's ARK adjusts with Beam, Compass, and Komatsu trades

Cathie Wood’s ARK ETFs disclosed their daily trades for Thursday, 3rd July 2025, with a mix of buys and sells across various sectors. The most significant trade of the day involved the sale of KOMATSU LTD (TYO:6301) shares, with ARKX (NYSE... Full story

Yahoo Finance • 9 months ago

Cathie Wood's ARK ETFs buy Aerovironment, trim Roblox stock

Cathie Wood’s ARK ETFs have reported their daily trades for Wednesday, July 2nd, 2025, showcasing a mix of aggressive buys and strategic sells that may signal the firm’s shifting investment focus. The largest transaction of the day involve... Full story

Yahoo Finance • 9 months ago

Cathie Wood's ARK ETF adjusts portfolio, buys Tesla and ATAI stock

Cathie Wood’s ARK ETFs have made their latest round of daily trades on Tuesday, 01 July 2025, with significant activity across a variety of sectors. In a notable move, ARK has increased its holdings in Tesla Inc (NASDAQ:TSLA) with a substa... Full story

Yahoo Finance • 9 months ago

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

PALM BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Worldwide, there is a rising demand for neuropsychiatric disorder treatments which is expected to fuel the global markets for years to come. With expand... Full story

Yahoo Finance • 10 months ago

Compass Pathways stock holds Buy rating on positive depression trial

Investing.com - H.C. Wainwright maintained its Buy rating and $45.00 price target on Compass Pathways (NASDAQ:CMPS) following breakthrough clinical trial results for its psilocybin therapy. The global treatment-resistant depression market... Full story

Yahoo Finance • 10 months ago

Compass Pathways price target lowered to $7 by BTIG on drug concerns

Investing.com - BTIG lowered its price target on Compass Pathways (NASDAQ:CMPS) to $7.00 from $12.00 on Tuesday while maintaining a Buy rating, citing concerns about the company’s COMP360 drug development. For deeper insights into CMPS’s f... Full story

Yahoo Finance • 10 months ago

Tesla, Regencell lead market cap stock movers this Monday

Monday’s market has seen significant movements across various stocks, with companies like Tesla Motors (NASDAQ:TSLA) and Regencell Bioscience Holdings (RGC) experiencing notable changes. These intra-day stock movements are driven by a mi... Full story

Yahoo Finance • 10 months ago

Compass plummets as late-stage data on psychedelic asset for depression disappoints

[Microdosing concept.Dried psilocybin mushrooms Golden Teacher.Psychedelic Psilocybe Cubensis mushrooms. Medical use.Microdosing.] IURII BUKHTA/iStock via Getty Images Compass Pathways (NASDAQ:CMPS [https://seekingalpha.com/symbol/CMPS])... Full story